All Stories

Bristol Myers Squibb notches overall survival win with Opdivo in pre-operative NSCLC

Bristol Myers Squibb has bolstered its case for Opdivo to be used as a pre-operative treatment for non-small cell lung cancer (NSCLC) as it has delivered an overall survival (OS) edge when added to chemotherapy.

Feb 19, 2025 - 16:43
 0
Bristol Myers Squibb notches overall survival win with Opdivo in pre-operative NSCLC
Bristol Myers Squibb has bolstered its case for Opdivo to be used as a pre-operative treatment for non-small cell lung cancer (NSCLC) as it has delivered an overall survival (OS) edge when added to chemotherapy.
Read More

Tags:

Previous Article

Four Seasons, Nashville Collaborates with Lucid Motors for Complimentray EV Cars...

Next Article

Ascletis' swift surge into obesity continues with competitive oral GLP-1 data

Related Posts

Johnson & Johnson CEO Joaquin Duato takes a 14% pay cut to $24.3M

Johnson & Johnson CEO Joaquin Duato takes a 14% pay cut...

Mar 12, 2025  0

FDA slaps China-based API makers with separate warning letters outlining quality, testing shortfalls

FDA slaps China-based API makers with separate warning ...

Feb 11, 2025  0

After Hetlioz’s rejection in jet lag disorder, Vanda sues FDA for right to promote off-label use

After Hetlioz’s rejection in jet lag disorder, Vanda su...

Apr 11, 2025  0